Differential Expression of Stem Cell Markers in Proliferating Cells in Glioma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2021 Jun 25

PMID 34170383

Citations 9

Authors

Marten Rehfeld

Jakob Matschke

Christian Hagel

Kerstin Willenborg

Markus Glatzel

Christian Bernreuther

Affiliations

Soon will be listed here.

Abstract

Purpose: The identification of prognostically and therapeutically relevant molecular markers is fundamental to the further development of personalised therapies in brain tumours. Current therapeutic options for the treatment of gliomas rely mainly on surgical resection and the inhibition of tumour cell proliferation by irradiation and chemotherapy. Glioma stem cells are a subpopulation of proliferating tumour cells that have self-renewal capacity and can give rise to heterogeneous cells that comprise the tumour and are thought to play a role in the resistance of gliomas to therapy. The aim of this study was to evaluate the expression of markers of glioma stem cells and differentiated glial cells in proliferating glioma cells in comparison to the overall expression of the respective markers in the tumour tissue.

Methods: Tissue microarrays were assembled from specimen of pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, ependymoma, and anaplastic ependymoma. These were immunohistochemically double stained with antibodies against the proliferation-associated antigen Ki67 and marker proteins for glioma stem cells (CD133, Nestin, Musashi, CD15, CD44), and differentiated glioma cells (GFAP, MAP2c).

Results: The expression of both glial and glioma stem cell markers differs between proliferating and non-proliferating glioma cells. Furthermore, the proliferating cells in the different glial tumour entities show a different expression profile.

Conclusion: Further analysis of marker expression in proliferating glioma cells and correlation with clinical outcome and susceptibility to irradiation and chemotherapy might help establish new biomarkers and therapies for glioma.

Citing Articles

Regulation of a novel circATP8B4/miR-31-5p/nestin ceRNA crosstalk in proliferation, motility, invasion and radiosensitivity of human glioma cells.

Luo D, Luo A, Ye G, Li D, Hu S, Zhao H J Radiat Res. 2024; 65(6):752-764.

PMID: 39287101 PMC: 11630049. DOI: 10.1093/jrr/rrae064.

Navigating glioblastoma complexity: the interplay of neurotransmitters and chromatin.

Romero-Reyes J, Vazquez-Martinez E, Silva C, Molina-Hernandez A, Diaz N, Camacho-Arroyo I Mol Biol Rep. 2024; 51(1):912.

PMID: 39153092 PMC: 11330389. DOI: 10.1007/s11033-024-09853-3.

Significance of Nestin and CD133 as cancer stem cell markers in diffuse glioma and association with p53 expression and IDH status.

Selvaraj S, Srinivas B, Verma S, Ms G Int J Clin Exp Pathol. 2024; 17(7):208-218.

PMID: 39114503 PMC: 11301415. DOI: 10.62347/YXVS6225.

M6A-methylated circPOLR2B forms an R-loop and regulates the biological behavior of glioma stem cells through positive feedback loops.

Lin H, Cui Z, E T, Xu H, Wang D, Wang P Cell Death Dis. 2024; 15(8):554.

PMID: 39090090 PMC: 11294345. DOI: 10.1038/s41419-024-06946-6.

Aptamers for the Delivery of Plant-Based Compounds: A Review.

Gamboa J, Lourenco P, Cruz C, Gallardo E Pharmaceutics. 2024; 16(4).

PMID: 38675202 PMC: 11053555. DOI: 10.3390/pharmaceutics16040541.

References

Pfenninger C, Roschupkina T, Hertwig F, Kottwitz D, Englund E, Bengzon J . CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res. 2007; 67(12):5727-36. DOI: 10.1158/0008-5472.CAN-07-0183. View

Hussain S, Yang D, Suki D, Aldape K, Grimm E, Heimberger A . The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006; 8(3):261-79. PMC: 1871955. DOI: 10.1215/15228517-2006-008. View

Thon N, Damianoff K, Hegermann J, Grau S, Krebs B, Schnell O . Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol Cell Neurosci. 2008; 43(1):51-9. DOI: 10.1016/j.mcn.2008.07.022. View

Sottoriva A, Spiteri I, Piccirillo S, Touloumis A, Collins V, Marioni J . Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013; 110(10):4009-14. PMC: 3593922. DOI: 10.1073/pnas.1219747110. View

Misra S, Hascall V, Markwald R, Ghatak S . Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol. 2015; 6:201. PMC: 4422082. DOI: 10.3389/fimmu.2015.00201. View

Dahlrot R, Hermansen S, Hansen S, Kristensen B . What is the clinical value of cancer stem cell markers in gliomas?. Int J Clin Exp Pathol. 2013; 6(3):334-48. PMC: 3563206. View

Christensen K, Schroder H, Kristensen B . CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol. 2008; 90(2):157-70. DOI: 10.1007/s11060-008-9648-8. View

Doetsch F, Caille I, Lim D, Garcia-Verdugo J, Alvarez-Buylla A . Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999; 97(6):703-16. DOI: 10.1016/s0092-8674(00)80783-7. View

Kanemura Y, Mori K, Sakakibara S, Fujikawa H, Hayashi H, Nakano A . Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation. 2001; 68(2-3):141-52. DOI: 10.1046/j.1432-0436.2001.680208.x. View

10.

Eng L, Ghirnikar R, Lee Y . Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res. 2000; 25(9-10):1439-51. DOI: 10.1023/a:1007677003387. View

11.

Reifenberger G, Sieth P, Niederhaus M, WECHSLER W . Expression of CD15 in tumours of the nervous system. Histochem J. 1992; 24(11):890-901. DOI: 10.1007/BF01046360. View

12.

Strojnik T, Rosland G, Sakariassen P, Kavalar R, Lah T . Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol. 2007; 68(2):133-43. DOI: 10.1016/j.surneu.2006.10.050. View

13.

Gunther H, Schmidt N, PHILLIPS H, Kemming D, Kharbanda S, Soriano R . Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2007; 27(20):2897-909. DOI: 10.1038/sj.onc.1210949. View

14.

Hale J, Sinyuk M, Rich J, Lathia J . Decoding the cancer stem cell hypothesis in glioblastoma. CNS Oncol. 2014; 2(4):319-30. PMC: 3873749. DOI: 10.2217/cns.13.23. View

15.

Pietras A, Katz A, Ekstrom E, Wee B, Halliday J, Pitter K . Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014; 14(3):357-69. PMC: 3999042. DOI: 10.1016/j.stem.2014.01.005. View

16.

Blumcke I, Becker A, Normann S, Hans V, Riederer B, Krajewski S . Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol. 2001; 60(10):984-93. DOI: 10.1093/jnen/60.10.984. View

17.

Ikota H, Kinjo S, Yokoo H, Nakazato Y . Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol. 2006; 111(5):475-82. DOI: 10.1007/s00401-006-0060-1. View

18.

Brown D, Mantamadiotis T . Insights into the next generation of cancer stem cell research. Front Biosci (Landmark Ed). 2014; 19(7):1015-27. DOI: 10.2741/4264. View

19.

Ma Y, Mentlein R, Knerlich F, Kruse M, Mehdorn H, Held-Feindt J . Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol. 2007; 86(1):31-45. DOI: 10.1007/s11060-007-9439-7. View

20.

Chen J, McKay R, Parada L . Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012; 149(1):36-47. PMC: 3719882. DOI: 10.1016/j.cell.2012.03.009. View